A Glimmer of Hope for Beta-Blockers in Heart Failure from Diastolic Dysfunction
SOURCE: Lund LH, et al. Association between use of beta-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA 2014;312:2008-2018.
Despite the consistent success of ACE inhibitors, angiotensin II receptor blockers, beta-blockers, and aldosterone antagonists in chronic heart failure from systolic dysfunction (s-CHF), trials of pharmacotherapy for chronic heart failure from diastolic dysfunction (d-CHF) have been disappointing. Modestly encouraging results for d-CHF were seen with candesartan (Atacand) in the CHARM-PRESERVED trial and nebivolol (Bystolic) in the SENIORS trial (for the d-CHF subgroup), but neither trial had strong enough outcomes to definitively establish a role in CHF.
Lund et al report on data obtained from national data registries in Sweden inclusive of 19,083 patients with d-CHF (termed “heart failure with preserved ejection fraction” in this article). The registry (41,976 patients) allowed comparison of patients who had been treated with beta-blockers vs those who had not by propensity scores. The primary outcome of the study was all-cause mortality.
Five-year survival in d-CHF was 7% higher in patients who were treated with beta-blockers. Because these data are observational in nature, they cannot definitively establish whether beta-blocker treatment reduces mortality in d-CHF, but they provide strong impetus to perform a large randomized trial to ultimately answer the question.
Because these data are observational in nature, they cannot definitively establish whether beta-blocker treatment reduces mortality in d-CHF, but they provide strong impetus to perform a large randomized trial to ultimately answer the question.Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.